News

SUBSCRIBE TO OUR NEWSLETTER

March 27, 2024

Psychedelic Alpha

ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient”

While MDMA-AP may be a promising therapy for PTSD,” he continued, “functional unblinding in the clinical trials and additional concerns around trial design and conduct leave many uncertainties about the balance of benefits and harms.

March 17, 2024

Double Blind

Meet the Influential, Innovative, and Disruptive Women in Psychedelics

Trailblazer Alert: Melissa Lavasani Featured Among Influential Women in Psychedelics

March 13, 2024

Business Wire

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc., a clinical-stage biopharmaceutical company…announced that the FDA has granted BTD to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD. If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

March 7, 2024

Yahoo!Finance

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

MindMed has become the fourth organization to be granted FDA Breakthrough Therapy Designation for a psychedelic drug candidate.

February 26, 2024

CNN

These athletes suffered life-changing injuries. Then, they turned to psychedelics

Daniel Carcillo, former NHL star, and PMC Board Member, shares his transformative journey from battling severe depression and dementia-like symptoms due to concussions, to finding renewed hope for life through psilocybin therapy.

February 9, 2024

Lykos Therapeutics

Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD

The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of August 11, 2024. If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy

January 21, 2024

Wondermed

11 Influential People Driving Progress in Psychedelics Today

Melissa Lavasani, MS, MPP, is a leading voice in the push for legislative reform surrounding psychedelics. She’s committed to improving safe, equitable access to psychedelic medicines through her advocacy work, lobbying efforts, and initiates to educate policymakers.

December 15, 2023

Hopkins Business of Health Initiative

Psychedelics in Focus: Treatment, Business, and Policy Futures

Join leading experts as they navigate the intricacies of psychedelic treatment, its economic implications, and the policy frontier that will define its role in mental health care

December 12, 2023

Psychedelic Alpha

BREAKING: MAPS PBC Files New Drug Application for MDMA-Assisted Therapy for PTSD

MDMA-assisted therapy becomes the first psychedelic therapy submitted to the FDA for approval

October 18, 2023

JHU Hub

Pioneering psychedelics researcher Roland Griffiths dies at 77

Roland Griffiths, an internationally revered researcher of psychedelic and mood-altering drugs, whose research helped kickstart a new era of psychedelic study and led to the creation of the nation's first psychedelic research center, at Johns Hopkins, died on Monday, Oct. 16, at age 77.

October 7, 2023

AP News

California Gov. Gavin Newsom vetoes bill that would have decriminalized psychedelic mushrooms

California Governor Gavin Newsom recently vetoed a bill to decriminalize psilocybin.

September 1, 2023

Anti-Hero’s Journey Podcast

Malissa Lavasani, Founder/CEO of Psychedelic Medicine Coalition

PMC Founder Melissa Lavasani recently joined Doc Askins’ Anti-Hero’s Journey podcast to share her story and journey in the psychedelic space.

August 25, 2023

Psychedelics Today Podcast

PT435 – The Federal Right to Try Act, The Farm Bill, and the Constant Balance Between Risk and Regulation

Listen to a captivating conversation between members of our board, Joe Moore from Psychedelics Today and Satya T., a policy expert at Arnold & Porter and PMC advisory board member.

August 15, 2023

Psychiatric News (American Psychiatric Association)

Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy

The move makes Australia the first nation to legalize the therapeutic use of psilocybin and MDMA in a controlled medical setting.

August 8, 2023

The Green Rush Podcast

Green Rush Podcast: Revisiting Melissa Lavasani

Founder, Melissa, was featured on the Green Rush Podcast to discuss the political advancement of psychedelic therapies!

July 26, 2023

The Dales Report

Lavasani On Psychedelics Advocacy With Government

Part of the advocacy process means pushing for more education and changing the narrative.

July 14, 2023

Grassroots Marketing

Psychedelic Science 2023: Psychedelic Medicine CEO, Melissa Lavasani

PMC founder Melissa Lavasani was recently featured on Grassroots Marketing podcast to discuss federal psychedelic legalization!

July 13, 2023

Reuters

US lawmakers make bipartisan push for psychedelics research in defense bill

Rep. Alexandria Ocasio-Cortez and Rep. Dan Crenshaw don’t always agree, but they are on the same side when it comes to helping veterans through psychedelic therapy.

June 20, 2023

UC Berkeley Center for the Science of Psychedelics

New National Poll: More Than 60 Percent of U.S. Voters Support Legalizing Psychedelic Therapy

A study from UC Berkeley shows that 61% of Americans support legalizing regulated therapeutic access.

June 8, 2023

Lucid

Powerful D.C. Republicans Drive Psychedelic Research Efforts

“PMC is the only Washington, D.C.-based member association working on psychedelic medicine policy, and we see this as an opportunity to engage with the U.S. government in a very practical way, and that means lawmakers on both sides of the aisle,” explained Lavasani

June 1, 2023

BrainFutures

Psychedelic Access Pathways

There are important legal distinctions between medical, religious, and wellness uses of psychedelic compounds.

May 26, 2023

Politico

K Street warms up to psychedelics

Advocates for rescheduling psychedelics like psilocybin, the hallucinogen found in magic mushrooms, to allow for investments in research of the drug, are finding some powerful allies for the cause

May 5, 2023

Benzinga

NIDA Partners With The National Institute Of Mental Health To Study Psychedelics Potential

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), said that psychedelic substances have promising potential for therapeutic uses, particularly for treating severe depression, post-traumatic stress disorder (PTSD) and addiction.

May 2, 2023

Globenewswire.

American Medical Association to Issue First New Code for Psychedelic Therapies

COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved

April 20, 2023

Peggyvandeplassche

How Psychedelics are Taking Capitol Hill by Storm

One of the goals of the organization is to influence Congress to develop an entire comprehensive policy outlook. There is a lot of urgency around this issue and it is important to get it right, as it is very challenging to undo bad policies.

Our Mission

Psychedelic Medicine Coalition (PMC) is a Washington, D.C.-based, nonpartisan 501(c)(3) nonprofit organization dedicated to advancing the research, policy, and responsible implementation of psychedelic medicine in U.S. healthcare through federal and state advocacy.

PMC is committed to expanding treatment options by integrating psychedelic medicines into mainstream healthcare through evidence-based policy, strategic partnerships, and public education.

Get in Touch